- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01750970
Endoscopic Resection of Bladder Tumors
September 20, 2016 updated by: Hopital Foch
Endoscopic Resection of High Grade(TA, T1, Cis)Non-muscle Invasive Bladder Tumors: Modification of Usual Management of This Resection by Using the Blue Light and Evaluation of the Outcome: Should we Maintain the Dogma of Second Endoscopic Resection as a Principle?
To confirm the benefit of endoscopic resection under fluorescence and blue light of high grade non-muscle invasive bladder tumor, and verifying if the second endoscopic resection recommended nowadays can be deleted.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Suresnes, France, 92150
- Hopital Foch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 year-old and older male and female subjects having high grade non-muscle invasive bladder tumor, with urinary cytology , imaging examination (Ultrasound, urography, or scan) and endoscopic examination
Exclusion Criteria:
- Less than 18 years of age, and having no:
- Non-muscle invasive tumor, and of low grade.
- Bladder tumor infiltrating the muscular layer shown by pre-operative test, with absence of urinary cytology
- No blue light source in sustainable way
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Resection under blue light
|
Endoscopic resection
|
|
Active Comparator: Resection under white light
|
Endoscopic resection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of extra lesions revealed by blue light compared to the resection performed in white light
Time Frame: 2 to 6 weeks after resection
|
2 to 6 weeks after resection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Henry BOTTO, MD, Hôpital FOCH 40, rue Worth 92150 Suresnes
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
December 11, 2012
First Submitted That Met QC Criteria
December 13, 2012
First Posted (Estimate)
December 17, 2012
Study Record Updates
Last Update Posted (Estimate)
September 21, 2016
Last Update Submitted That Met QC Criteria
September 20, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009/34
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Tumor
-
Seoul National University HospitalUnknownProstate Cancer | Bladder Cancer | Bladder Tumor | Prostate Tumor
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
University of Rome Tor VergataUniversity Of Perugia; University of L'AquilaCompletedBladder Cancer TNM Staging Primary Tumor (T) Ta | Bladder Cancer TNM Staging Primary Tumor (T) T1 | Bladder Cancer Transitional Cell GradeItaly
-
Ikena OncologyBristol-Myers SquibbCompletedNeoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditionsUnited States
-
Careggi HospitalCompleted
-
UroSee CorporationUnknownBladder TumorUnited States
-
Chinese University of Hong KongUnknownUrinary Bladder TumorHong Kong
-
Case Comprehensive Cancer CenterWithdrawnNon-muscle Invasive Bladder Cancer (NMIBC) | Bladder Tumor (TURBT)United States
-
H. Lee Moffitt Cancer Center and Research InstituteJohns Hopkins University; National Institutes of Health (NIH)WithdrawnBladder Cancer | Urothelial Carcinoma | Bladder TumorUnited States
-
Medical University of WarsawUnknownBladder Tumor | Transurethral Resection | Spinal AnaesthesiaPoland
Clinical Trials on Endoscopic resection under blue light (Hexvix®)
-
Hospital Pedro HispanoUnknownBleeding After Resection of Colorectal Neoplastic LesionsPortugal
-
Medical Dermatology SpecialistsDUSA Pharmaceuticals, Inc.CompletedActinic Keratosis | Skin Cancer | Non-melanoma Skin Cancer | Sun Damaged SkinUnited States
-
The Center for Clinical and Cosmetic ResearchSun Pharmaceutical Industries LimitedCompletedFacial Cutaneous Squamous Cell Carcinoma in SituUnited States
-
Edward Maytin, MD, PhDDUSA Pharmaceuticals, Inc.CompletedBasal Cell Nevus SyndromeUnited States
-
Northwestern UniversityActive, not recruiting
-
PhotocureCatalyst Pharmaceutical ResearchRecruiting
-
University Hospital, LimogesGalderma R&DCompleted
-
Taisho Pharmaceutical IndonesiaTrisakti University; Atma Jaya Catholic University of IndonesiaCompletedAthletic Performance | Heat StressIndonesia
-
Massachusetts General HospitalCompletedAcne VulgarisUnited States
-
Sun Pharmaceutical Industries, Inc.RecruitingActinic KeratosisUnited States